Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

AC Immune ACIU

Healthcare — Biotechnology

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
0.06
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — 1 1 — — — —
Insider Ownership
36.59%

Capital & Financial Ratios

Market Cap
272.75
Revenue
4.64
Net Income
(52.63)
Free Cash Flow
(83.67)
Net Debt
(95.35)
Current Ratio
0.93
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
55.94
P/B ratio
5.83
Past 5Y EPS Growth
3.28%
This Y EPS Growth
39.25%
Next Y EPS Growth
148.39%
Next 5Y EPS Growth
7.55%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 114.79 187.98 110.33 95.35
Receivables 17.18 1.25 1.18 17.00
Inventory — — — —
Other 0.27 1.25 0.43 0.26
139.41 195.37 116.74 118.18
2023 2024 2025 Q'26
Payables 1.87 3.02 2.50 1.91
ST’ Debt — — — —
Other — — — —
15.12 114.54 114.29 126.83
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 1.43 — — —
—
’25 1.10 1.58 1.17 0.45
4.31
’24 — 0.76 29.45 0.81
31.02
’23 — — — —
16.49
’22 — — 4.07 0.05
4.12
’20 12.83 1.33 1.22 1.08
16.46
’19 75.31 1.51 33.91 1.02
111.75
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 — (19.80) — —
—
’25 (20.93) (20.79) (24.20) (17.68)
(83.60)
’24 1.17 80.71 (12.65) 5.57
74.79
’23 (18.16) (16.24) (15.65) (17.24)
(67.29)
’22 (25.06) (19.08) (13.99) (18.96)
(77.09)
’21 (19.17) (17.45) (15.52) (19.73)
(71.87)
’20 (10.02) (15.47) (18.18) (19.82)
(63.48)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 — (20.34) — —
—
’25 (21.33) (21.26) (24.30) (17.78)
(84.67)
’24 0.89 80.64 (12.87) 5.47
74.14
’23 (18.37) (16.41) (15.98) (17.42)
(68.18)
’22 (25.65) (19.61) (14.12) (19.02)
(78.39)
’21 (20.04) (18.14) (16.05) (20.52)
(74.75)
’20 (10.24) (15.86) (18.48) (20.66)
(65.23)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.19) — — —
—
’25 (0.21) (0.25) (0.20) (0.18)
(0.84)
’24 (0.21) (0.25) 0.06 (0.18)
(0.58)
’23 (0.23) (0.22) (0.20) (0.06)
(0.71)
’22 (0.25) (0.24) (0.17) (0.24)
(0.89)
’21 (0.25) (0.29) (0.24) (0.28)
(1.06)
’20 (0.11) (0.23) (0.28) (0.30)
(0.92)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 1.68 1.78 2.25 1.43 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 5.21 5.14 5.04 4.00 — — —
High Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 156 161 172 122 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ 0.03 0.10 0.18 0.04 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — 4.12 16.49 31.02 4.31 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 100.00% 100.00% 100.00% 100.00% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (74.13) (60.40) (57.83) (85.03) — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ (1,797.71%) (366.35%) (186.43%) (1,971.65%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (74.14) (60.41) (57.84) (85.03) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.47 2.47 2.46 3.02 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ 0.05 0.19 0.31 0.04 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.89) (0.71) (0.58) (0.84) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.92) (0.79) 0.75 (0.83) — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.02) (0.01) (0.01) (0.01) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.94) (0.80) 0.74 (0.84) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.12 2.11 1.28 0.54 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 83.55 84.70 99.69 100.75 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡ — 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — 28.75 61.84 8.66 73.36 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — 1.04 2.22 2.11 5.84 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — 9.22 44.38 2.70 48.38 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — (0.76) (4.18) 1.13 (2.46) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (77.09) (67.29) 74.79 (83.60) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.30) (0.89) (0.65) (1.07) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (78.39) (68.18) 74.14 (84.67) ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 122.20 124.29 80.83 2.45 — — —
Working Cap'
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.03 — — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (125.43) (114.79) (187.98) (110.33) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 177.09 178.94 127.53 54.18 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (30.84%) (30.32%) (24.83%) (37.92%) — — —
ROA
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ (89.83%) (58.19%) 0.00% 0.00% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (34.41%) (33.94%) (37.74%) (93.59%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

AC Immune (ACIU), a Swiss biotech powerhouse targeting Alzheimer’s and Parkinson’s through innovative immunotherapy, rides the razor-edge of biotech volatility, with its stock plunging over 75% from 2016 IPO peaks amid relentless share dilution and milestone-dependent revenue spikes. Partnerships with giants like Eli Lilly and Roche delivered windfall payments—propelling 2019 revenue to $111.7 million and brief profitability—but chronic losses, pipeline setbacks like Phase 2 flops, and a workforce doubling to 172 have eroded book value per share by 67%, fueling skepticism about sustainable momentum in a cash-burn sector.

Diving deeper, ACIU’s fundamentals flash warning lights: ROE cratered to -37.7%, free cash flow only recently turned positive at $0.74 per share, and insider trading remains silent. Yet, analyst forecasts ignite excitement, projecting revenue exploding 319% to $153.8 million by 2027 on Phase 2/3 catalysts for ACI-24 and Morphomer tech, flipping to $64 million profits and EPS of +$0.63, with mean price targets implying 123% upside (highs at 222%).

This binary bet in the ballooning $13 billion Alzheimer’s market tempts contrarians—is ACIU a dilution trap or undervalued disruptor poised for breakout amid Lilly’s donanemab shadow and regulatory hurdles? Cash runway to 2027 offers breathing room, but trial risks loom large.

Read full commentary →

AC Immune (ACIU) Latest News

News by impact score

Fine-tune

20 Aug

3 investorshub.advfn.com, 9:35 AM
AC Immune shares rise after encouraging early Phase 1 data for ACI-19764. Encouraging Phase 1 data for ACI-19764 can lift AC Immune's pipeline outlook and near-term stock sentiment without yet transforming long-term prospects.

3 , 7:00 AM
AC Immune announces positive preliminary Phase 1 data for NLRP3 inhibitor ACI-19764. Positive preliminary Phase 1 data advances pipeline development and may influence near-term sentiment without guaranteeing later-stage success.

11 Aug

4 stocktwits.com, 12:18 PM
AC Immune gains FDA Fast Track designation for its Parkinson’s disease therapy, sending ACIU stock toward its best day in over 10 months with retail investors expecting a breakout. FDA Fast Track status for core Parkinson’s therapy directly improves regulatory timeline and raises AC Immune valuation.

4 , 7:00 AM
AC Immune receives FDA Fast Track Designation for ACI-7104, an anti-alpha-synuclein active immunotherapy to treat early Parkinson’s Disease. FDA Fast Track Designation accelerates ACI-7104 development and review, strengthening AC Immune's position in Parkinson's therapies.

5 Aug

3 , 9:55 AM
AC Immune (ACIU) surpassed Q2 earnings and revenue estimates. Earnings beat offers short-term positive sentiment without shifting long-term trajectory.

3 , 7:00 AM
AC Immune releases financial results and corporate developments for first half of 2026. Half-year financial and corporate updates supply performance data that can shift near-term investor views on operations.

30 Jun

4 , 7:00 AM
AC Immune reports interim 12-month data from Phase 1b/2 ABATE trial of ACI-24 in prodromal Alzheimer’s disease. Interim Alzheimer's trial data for lead candidate can drive major valuation shifts and pipeline momentum.

11 Jun

3 , 7:00 AM
AC Immune secures research grant from Goradia Family to develop ACI-7104 for Parkinson’s Disease. Grant supplies targeted funding to advance ACI-7104 Parkinson’s program and may modestly support pipeline progress.

22 May

3 GlobeNewswire, 7:00 AM
AC Immune presented new Phase 1 data showing higher uptake of its TDP-43 PET Tracer ACI-19626 in patients with ALS. Positive Phase 1 results for ACI-19626 mark pipeline progress in ALS diagnostics.

12 May

4 GlobeNewswire, 7:00 AM
AC Immune announces the retirement of CEO Dr. Andrea Pfeifer at the upcoming Annual General Meeting. CEO retirement signals major leadership transition with potential to alter strategic direction and investor sentiment.

30 Apr

4 GlobeNewswire, 7:00 AM
AC Immune initiates final cohort in ongoing Phase 1b/2 ABATE trial of anti-Abeta active immunotherapy ACI-24.060 to treat Alzheimer's disease. Progressing to final cohort in Phase 1b/2 Alzheimer's trial marks significant clinical advancement boosting ACIU's pipeline value and investor sentiment.

3 Zacks, 8:30 AM
AC Immune (ACIU) reported a Q1 net loss but exceeded revenue estimates. Q1 revenue beat despite net loss moderately bolsters financial sentiment amid ongoing development costs.

3 GlobeNewswire, 7:05 AM
AC Immune reported first quarter 2026 financial results and corporate updates. Quarterly financial and corporate updates affect cash position, pipeline progress, and investor sentiment moderately.

12 Apr

4 Insider Monkey, 2:46 PM
Leerink Partners deems the amendment to AC Immune's (ACIU) tau program collaboration with Eli Lilly great news, highlighting positive progress for the Alzheimer's candidate. Leerink's endorsement of the Eli Lilly tau program amendment signals a major strategic boost to ACIU's pipeline and investor confidence.

9 Apr

3 Zacks, 10:29 AM
AC Immune (ACIU) stock surged 16.3% over the past week due to key developments warranting investor attention. 16.3% weekly rally reflects moderately noticeable positive influence on ACIU's market sentiment and trajectory.

7 Apr

4 www.fool.com, 5:14 PM
AC Immune (ACIU) stock surged nearly 15% higher today on positive clinical data from its Alzheimer's vaccine candidate, boosting investor confidence in the biotech's pipeline progress. Nearly 15% stock surge driven by favorable clinical results signals major boost to pipeline credibility and investor sentiment.

4 Simply Wall St., 3:10 PM
Eli Lilly extends its tau-targeting partnership with AC Immune to broaden Alzheimer's disease pipeline potential, building on prior collaboration for proteinopathy diagnostics and therapeutics. Eli Lilly's extension of the tau partnership provides AC Immune with major pharma validation and expanded Alzheimer's development opportunities, likely boosting market performance.

4 GlobeNewswire, 7:00 AM
AC Immune announces amendment to its Morphomer® Tau License and Collaboration Agreement with Lilly. Amendment to a key partnership with Lilly on Morphomer Tau technology could significantly alter ACIU's development timeline, milestones, and revenue prospects.

19 Mar

4 GlobeNewswire, 7:00 AM
AC Immune presented the first in vivo images of brain TDP-43 pathology from the Phase 1 trial of its PET tracer ACI-19626 at the AD/PD™ 2026 conference. First in vivo TDP-43 pathology images from Phase 1 trial validate ACI-19626's potential, advancing ACIU's neurodegenerative diagnostics pipeline and likely enhancing investor sentiment.

18 Mar

3 Zacks, 12:00 PM
AC Immune (ACIU) upgraded to Buy rating by analysts citing strong pipeline progress, positive clinical data, and undervalued shares. Analyst upgrade highlights pipeline advancements influencing market sentiment and moderate financial outlook.

13 Mar

4 GlobeNewswire, 7:00 AM
AC Immune (ACIU) reported full year 2025 financial results and provided a corporate update. Full year financial results and corporate updates disclose key financial health, pipeline progress, and strategic shifts that significantly impact investor sentiment and stock trajectory.

3 Associated Press Finance, 7:11 AM
AC Immune (ACIU) released its Q4 earnings snapshot. Q4 earnings snapshots impact financial performance and investor sentiment moderately for biotech firms like AC Immune.

24 Feb

4 GlobeNewswire, 7:00 AM
AC Immune has initiated a Phase 1 clinical trial for its NLRP3 inhibitor targeting neuroinflammation in neurodegenerative diseases. Initiating Phase 1 trial advances AC Immune's pipeline in a promising therapeutic area, likely driving positive investor sentiment and stock momentum.

13 Jan

3 Simply Wall St., 1:05 PM
AC Immune (ACIU) is highlighted as a top penny stock to watch in January 2026 due to its innovative approaches in developing therapies for neurodegenerative diseases. The company is focusing on its promising pipeline, which includes treatments for Alzheimer's disease and other related conditions. Investors are encouraged to monitor AC Immune's progress and market movements as it navigates the competitive landscape of biotech. AC Immune's advancements in neurodegenerative disease therapies may moderately influence its market performance and investor sentiment.

11 Dec

4 www.biopharmadive.com, 8:36 AM
AC Immune announced positive data from its clinical trials for a new immunotherapy targeting Parkinson's disease. The results indicate potential efficacy in slowing disease progression, which could lead to further development and commercialization efforts. This breakthrough positions AC Immune favorably in the competitive landscape of neurodegenerative disease treatments. Positive clinical trial results for a Parkinson's immunotherapy could significantly enhance AC Immune's market position and investor sentiment.

4 GlobeNewswireMotley FoolMT NewswiresGuruFocus.comMT NewswiresSimply Wall St.GuruFocus.com, 7:00 AM
AC Immune announced positive interim Phase 2 data for ACI-7104.056, indicating potential to slow the progression of Parkinson’s disease. The results suggest that the treatment may have a significant impact on disease management, enhancing the company's position in the neurodegenerative disease market. Further studies are anticipated to confirm these findings and assess long-term effects. Positive interim data from a Phase 2 trial could significantly influence AC Immune's future performance and market position in neurodegenerative treatments.

3 Associated Press Finance, 10:30 AM
AC Immune (ACIU) has been highlighted as one of the most active stocks in the market, indicating increased trading volume and investor interest. The company's recent developments and market activities have drawn attention, reflecting potential shifts in investor sentiment and market dynamics surrounding its operations. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.

5 Dec

3 Simply Wall St., 6:08 AM
AC Immune is facing scrutiny over its cash burn situation, raising concerns about its financial sustainability. The company has been investing heavily in research and development, which has led to significant cash outflows. Analysts are closely monitoring these developments as they could impact the company's ability to fund ongoing projects and maintain operations. The current cash reserves may not be sufficient to support long-term growth without additional funding or revenue generation. The cash burn situation may affect AC Immune's financial performance and operational capabilities, but it is not expected to drastically alter the company's overall trajectory.

11 Nov

3 GlobeNewswire, 7:00 AM
AC Immune will present at the Jefferies 2025 London Healthcare Conference, highlighting its ongoing commitment to advancing its pipeline and engaging with investors. The presentation is expected to provide insights into the company's strategic direction and developments in its research initiatives. The presentation may influence investor sentiment and provide updates on key developments, but it is not expected to fundamentally alter the company's trajectory.

4 Nov

4 Simply Wall St.ZacksSimply Wall St.Associated Press FinanceZacksSimply Wall St.Simply Wall St., 10:22 PM
AC Immune (ACIU) reported a narrowing of losses by 5.9% annually, indicating improved financial performance. The company forecasts a significant revenue growth of 55.6% ahead of its earnings report, suggesting positive market sentiment and potential for future expansion. Forecasted revenue growth of 55.6% indicates significant potential for future performance and investor interest.
© 2016–2026 stockrow.com Terms and Conditions Indicators Weekly Summary Contact Us